Foundayo FAQ: 31 Common Questions About Orforglipron Answered
Foundayo is Eli Lilly's once-daily GLP-1 pill for weight loss, FDA-approved April 1, 2026. Trial participants on the highest dose lost 12.4% of body weight; self-pay starts at $149 per month, $25 with commercial coverage.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Foundayo is a once-daily oral GLP-1 receptor agonist whose generic name is orforglipron, made by Eli Lilly and approved by the FDA on April 1, 2026 for long-term weight management in adults with obesity, or overweight with at least one weight-related condition [1][2][9]. In the 72-week ATTAIN-1 trial, people taking the highest dose lost an average of 12.4% of body weight (27.3 lb) under the efficacy estimand, or 11.1% in the label’s intent-to-treat analysis, compared with roughly 2% on placebo [1][4]. Self-pay through Lilly’s program starts at $149 per month for the lowest dose, eligible patients with commercial coverage may pay as little as $25, and eligible Medicare Part D beneficiaries may pay $50 per month through the Medicare GLP-1 Bridge [2][6][7].
This page answers the questions people ask most about Foundayo: what it is, how to take it, side effects and warnings, drug and birth-control interactions, trial results, cost and access, and what is still unknown. Dosing details below summarize the FDA-approved label; decisions about starting doses, dose changes, and restarting after a break belong with the prescriber.
What is Foundayo, and is it the same thing as orforglipron?
Yes. Foundayo is the brand name and orforglipron is the generic (active ingredient) name of the same medicine, an oral tablet taken once daily [1][2]. The FDA approved it under NDA 220934, effective April 1, 2026 [2][9]. It is Lilly’s second FDA-approved obesity medicine [2].
Is Foundayo a GLP-1, and how is it different from semaglutide and tirzepatide?
Foundayo is a GLP-1 receptor agonist: it binds to and activates the human GLP-1 receptor [1]. Chemically it is a small molecule (non-peptide) tablet, while semaglutide and tirzepatide are injectable incretin-based obesity medications, as the ATTAIN-MAINTAIN trial authors describe them [1][2][5]. The listed sources contain no head-to-head trial comparing Foundayo with Wegovy or Zepbound; the ATTAIN-MAINTAIN authors note their trial lacked an arm in which participants continued the injectable [5].
How do you pronounce Foundayo and orforglipron?
Lilly gives the pronunciation of Foundayo as fown-DAY-oh [2], and orforglipron as or-for-GLIP-ron [4].
Who makes Foundayo, and where did it come from?
Eli Lilly makes Foundayo. Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018; Chugai and Lilly published the preclinical pharmacology together, including a paper on the structural basis for GLP-1 receptor activation in PNAS in 2020 [2][4].
What is Foundayo approved to treat?
The label’s only indication is weight management: in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition [1][9]. Concomitant use with another GLP-1 receptor agonist is not recommended [1]. Safety and effectiveness in people under 18 have not been established [1][2].
Is Foundayo approved for type 2 diabetes?
No. The label’s indication is weight management only [1]. Lilly’s second-quarter 2026 results (reported August 5, 2026) list a U.S. submission of orforglipron for type 2 diabetes, and on June 8, 2026 Lilly announced results from three pivotal type 2 diabetes trials [10]. Beyond diabetes, Lilly says orforglipron is being studied for obstructive sleep apnea, knee osteoarthritis pain, hypertension, peripheral artery disease, and stress urinary incontinence [2].
How does Foundayo work in the body?
It binds and activates the human GLP-1 receptor. GLP-1 regulates appetite and caloric intake, and receptors sit in brain regions that regulate appetite; in animal studies, orforglipron distributed to and activated neurons in those regions [1]. The label says weight loss involves greater fat mass loss than lean mass loss, and that food intake falls, likely through decreased appetite [1]. Foundayo also delays gastric emptying, most after the first dose, diminishing over time [1].
What strengths does it come in, and what does the label’s escalation schedule say?
Tablets come in six strengths: 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg [1][2]. The label’s schedule, designed to reduce gastrointestinal adverse reactions, starts at 0.8 mg once daily, moves to 2.5 mg after at least 30 days, then 5.5 mg after at least 30 days, with further increases to 9, 14.5, or 17.2 mg each allowed after at least 30 days on the current dose, based on response and tolerability; the maximum is 17.2 mg once daily [1]. Any change to that schedule is a decision for the prescriber.
Why do trial reports say 36 mg when the top tablet is 17.2 mg?
The Phase 3 trials used investigational capsules of 1, 3, 6, 12, 24, and 36 mg [4][5]. Those capsule doses are equivalent to the approved tablets: 1 mg equals 0.8 mg, 3 mg equals 2.5 mg, 6 mg equals 5.5 mg, 12 mg equals 9 mg, 24 mg equals 14.5 mg, and 36 mg equals 17.2 mg [5]. The label presents trial data as equivalent dosages of the tablet [1]. In ATTAIN-1, everyone started at 1 mg and stepped up at four-week intervals to their randomized dose [4].
Does it need to be taken with food, water, or at a set time of day?
The label says to take it once daily, with or without food [1]. Lilly markets Foundayo as the only GLP-1 pill that can be taken any time of day without food or water restrictions — that claim is Lilly’s, not an independent finding [2][3]. A food-effect study using a 37.5 mg investigational tablet found AUC down 19% and Cmax down 26% fed versus fasted, with no change in time to peak or half-life, and the label concludes there is no clinically relevant food effect [1]. Absolute bioavailability was 77% at 0.8 mg, and esomeprazole 40 mg had no effect on exposure [1].
Can the tablet be split, crushed, or chewed?
No. The label says to swallow tablets whole, not to break, crush, or chew them, and not to take more than one tablet per day [1][2][3].
What does the label say about a missed dose?
The label says a missed dose should be taken as soon as possible, and the next dose should not be doubled [1]. If 7 or more consecutive doses are missed, the label says to reinitiate dosage escalation at a lower dosage to reduce the risk of GI adverse reactions, and Lilly’s patient materials say to call the healthcare provider about how to restart [1][2]. The elimination half-life is approximately 29 to 49 hours [1].
How is Foundayo stored, and how long does it last?
The FDA approval letter sets the expiry dating period at 24 months from the date of manufacture when stored at 20°C to 25°C [9]. As an oral non-peptide, orforglipron avoids the cold-chain distribution barrier of injectables, a point the ATTAIN-MAINTAIN authors make about scalability [5].
What are the most common side effects?
In the pooled placebo-controlled Trials 1 and 2, at the 5.5, 9, and 17.2 mg doses versus placebo: nausea 26%, 34%, and 35% versus 10%; constipation 20%, 27%, and 24% versus 9%; diarrhea 21%, 23%, and 25% versus 11%; and vomiting 13%, 21%, and 24% versus 4% [1]. Dyspepsia ran 12–16% versus 4%, abdominal pain 13–14% versus 7%, fatigue 6–9% versus 4%, and hair loss 4–5% versus 2% (7% in women versus 0.9% in men) [1].
Any GI reaction occurred in 60%, 68%, and 69% of treated patients versus 37% on placebo; of those reporting GI reactions, 60% were mild, 36% moderate, and 4% severe. Nausea, vomiting, and diarrhea were highest during dose escalation and decreased over time [1]. Heart rate rose 4 to 5 beats per minute versus 0.5 with placebo, and hypotension occurred in 2% versus 0.5% [1].
How many people quit Foundayo because of side effects?
Across both trials, 8% permanently discontinued due to adverse reactions (6% at 5.5 mg, 9% at 9 mg, 10% at 17.2 mg) versus 3% on placebo, mostly for GI reasons [1]. Overall trial-drug discontinuation in Trial 1 was 22%, 22%, and 24% by dose versus 30% on placebo [1].
What is the boxed warning about?
The boxed warning covers thyroid C-cell tumors. Foundayo is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2, and also in those with serious hypersensitivity to orforglipron or any excipient [1]. Notably, orforglipron is not pharmacologically active in rats or mice and produced no rodent tumors; the human relevance of the rodent class finding has not been determined [1]. The FDA also required a 15-year MTC registry case series [9].
What other serious warnings are on the label?
The label warns about acute pancreatitis (6 adjudicated events in 6 treated patients versus 2 events in 1 placebo patient), severe GI reactions (not recommended with severe gastroparesis), acute kidney injury from volume depletion, hypoglycemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, and gallbladder disease (cholelithiasis 1% versus 0.7%) [1]. On pulmonary aspiration during anesthesia or deep sedation, the data are insufficient to say whether changing preoperative fasting or pausing the drug helps; patients should tell providers about planned procedures [1].
Does Foundayo affect birth control pills?
Yes, potentially. The label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose escalation; non-oral hormonal contraceptives should not be affected [1][2]. The reason is that delayed gastric emptying may affect oral absorption — the effect on oral contraceptive absorption has not been evaluated in a clinical trial [1]. Because the label’s schedule includes five escalation steps above the starting dose, those 30-day windows can repeat with each increase [1].
What drugs interact with Foundayo?
Orforglipron is metabolized mainly by liver CYP3A4 [1]. With a strong CYP3A4 inhibitor, the maximum Foundayo dose is 9 mg daily; clarithromycin raised orforglipron AUC 3.5-fold, and verapamil, a moderate inhibitor, raised it 2-fold [1]. Strong inhibitors that also inhibit OATP1B, such as ritonavir, should be avoided; cyclosporine raised AUC 2.6-fold [1]. Strong CYP3A4 inducers should be avoided (carbamazepine cut AUC 82%); with moderate inducers such as efavirenz (AUC down 61%), the label says to monitor effectiveness and escalate as needed [1]. Simvastatin should not exceed 20 mg daily (simvastatin acid exposure roughly doubled); rosuvastatin and atorvastatin showed no clinically relevant change [1]. Delayed gastric emptying can also affect absorption of other oral medications [1].
Can it be taken with insulin or a sulfonylurea?
The label warns that combining Foundayo with insulin or an insulin secretagogue (such as a sulfonylurea) can raise the risk of hypoglycemia, including severe episodes, and says reducing the dose of those medicines may be necessary when starting Foundayo [1]. In Trial 2, 7% of patients taking Foundayo with a sulfonylurea reported hypoglycemia versus 0.5% not on a sulfonylurea [1]. Any change to diabetes medicines is the prescriber’s call.
What about kidney, liver, pregnancy, breastfeeding, and older adults?
No dosage change is needed for any level of renal impairment, including end-stage renal disease; 87% of a dose is recovered in feces and less than 1% in urine [1]. Severe hepatic impairment (Child-Pugh C) is a do-not-recommend: AUC rose 1.7-fold in moderate and 4.6-fold in severe impairment, and the label recommends no dosage modification for mild or moderate hepatic impairment (Child-Pugh A and B) [1]. In pregnancy, weight loss offers no benefit and may cause fetal harm; the label says to discontinue when pregnancy is recognized, and a pregnancy exposure registry can be reached at 1-800-545-5979 [1][9]. Breastfeeding is not recommended — rat milk concentrations were 3-fold plasma levels and there are no human milk data [1]. In trials, 13% of treated patients were 65 or older (1% 75 or older), with no overall differences in safety or effectiveness [1].
How much weight did people lose in the pivotal trials?
ATTAIN-1 enrolled 3,127 adults without diabetes (average baseline 103.2 kg, BMI 37) for 72 weeks [1][4]. At the highest dose (36 mg capsule, equivalent to the 17.2 mg tablet), the efficacy estimand — everyone staying on treatment — showed -12.4% (27.3 lb) versus -0.9% (2.2 lb) on placebo; the treatment-regimen estimand showed -11.2% (25 lb) versus -2.1% (5.3 lb) [4][2]. The label’s intent-to-treat analysis shows -11.1% versus -2.1%, with 71.5% losing at least 5% (versus 26.8%), 35.9% at least 15% (versus 6%), and 18.4% at least 20% (versus 2.9%) [1]. Under the efficacy estimand at 36 mg, 77.1% lost at least 5%, 59.6% at least 10%, 39.6% at least 15%, and 20.1% at least 20% [4]. In Trial 2 (1,613 adults with type 2 diabetes), the 17.2 mg group lost 9.6% versus 2.5% on placebo by intent-to-treat [1].
Did Foundayo improve anything besides weight?
In ATTAIN-1 at the highest dose (efficacy estimand), waist circumference fell 11.1 cm versus 2.1 cm, non-HDL cholesterol 8.5% versus 1.4%, triglycerides 21.6% versus 4.8%, and systolic blood pressure 6.7 versus 0.8 mmHg; a pre-specified exploratory analysis showed hsCRP down 47.7% [4]. Among 1,127 participants with prediabetes, up to 91% on orforglipron reached near-normal blood sugar versus 42% on placebo [4].
What happened when people switched from Zepbound or Wegovy?
ATTAIN-MAINTAIN randomized 376 participants at 29 U.S. sites between September 2024 and November 2025, all previously in the SURMOUNT-5 study: 205 from tirzepatide and 171 from semaglutide, assigned to orforglipron 36 mg capsule or maximum tolerated dose, or placebo [5]. At week 52, plateaued participants kept 74.7% of their prior weight loss on orforglipron versus 49.2% on placebo in the tirzepatide cohort, and 79.3% versus 37.6% in the semaglutide cohort [5]. In the tirzepatide cohort, 43.7% kept at least 80% of their prior loss versus 16.4% on placebo [5]. Limitations: no arm continued the injectable, and the trial lasted one year [5]. Lilly’s FAQ says switch dosing is for the doctor to decide [3].
Does the weight come back if you stop?
The placebo arms of ATTAIN-MAINTAIN — people who stopped injectable therapy without orforglipron — kept only 49.2% (tirzepatide cohort) and 37.6% (semaglutide cohort) of their prior weight reduction at week 52 [5]. That is the closest the listed sources come to an off-drug answer; no dedicated discontinuation trial of Foundayo itself appears in them.
How much does Foundayo cost?
Lilly’s regular self-pay prices per 30-day supply are $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), and $349 (14.5 and 17.2 mg) [6]. Current program prices differ:
| Dose | Lilly regular self-pay | Current program price |
|---|---|---|
| 0.8 mg | $149 | $149 |
| 2.5 mg | $199 | $149 (temporary, through December 31, 2026) |
| 5.5 mg | $299 | $199 (temporary, through December 31, 2026) |
| 9 mg | $299 | $299 |
| 14.5 mg | $349 | $299 with the Self-Pay Journey Program if refilled within 45 days |
| 17.2 mg | $349 | $299 with the Self-Pay Journey Program if refilled within 45 days |
These are program prices with terms, not the list price. The list price (WAC) is $649 per 30-day supply, per AnalySource data accessed April 3, 2026 [12]. GoodRx lists retail cash prices of $739.80 to $788.68 per 30 tablets with an average retail price of $782.90; its coupon prices are dated 09/14/26, and the program is not insurance, with taxes and fees possibly applying [13][6].
What does the savings card cover, and who is excluded?
With a commercial plan that covers Foundayo, the card brings the cost to as little as $25 for a 1-, 2-, or 3-month fill, with savings capped at $100, $200, or $300 per fill respectively and $1,000 per calendar year, up to 10 fills per year; the card expires December 31, 2026 [6][12]. With a commercial plan that does not cover it, prices are $149 (0.8 and 2.5 mg), $199 (5.5 mg), and $299 (9, 14.5, 17.2 mg), with monthly savings caps of $520, $470, or $370 [6]. Excluded: Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, DoD, VA, TRICARE, and state drug assistance members; participants must be 18 or older and U.S. or Puerto Rico residents, and members of alternate funding programs are excluded [6]. FSA/HSA eligibility varies by plan [3][6].
How does the Medicare GLP-1 Bridge work?
The CMS Medicare GLP-1 Bridge demonstration runs July 1, 2026 through December 31, 2027 for eligible Part D beneficiaries [7]. The copay is $50; the Bridge operates outside the Part D benefit’s coverage and payment flow, so the Part D deductible does not apply, no part of the copay counts toward TrOOP, and there is no low-income subsidy [7]. In 2026 a single central processor handles prior authorization and claims, and a prior authorization form exists; eligibility follows the Bridge’s clinical criteria and is not a guarantee of coverage [7][6]. Details are at Medicare.gov/glp1bridge and 1-800-MEDICARE, and Lilly says eligible Part D patients may get Foundayo for $50 per month [7][2].
Where can you fill it, and is there a generic?
LillyDirect accepted prescriptions from approval, began shipping April 6, 2026, with retail pharmacies and telehealth following [2]. LillyDirect fills through four dispensing pharmacies — Amazon Pharmacy, Fuze Health, Gifthealth, and Walmart Pharmacy — with free delivery or retail pickup and savings applied automatically [3]. GoodRx lists the $149 manufacturer offer for the 0.8 mg dose at Walgreens, Walmart, CVS, Costco, Sam’s Club, Target, Hy-Vee, Dillons, and others [13]. There is no generic — it is brand only [13]. Lilly has submitted orforglipron in more than 40 countries [2], and Q2 2026 Foundayo revenue was $98 million [10].
What are patients reporting so far?
Drugs.com shows an average rating of 7.0 out of 10 from 40 reviews, with 50% positive and 13% negative [8]. Nausea, constipation, and fatigue are the side effects most often mentioned in reviews [8]. Recurring themes from May to September 2026 include reduced appetite and food noise and the lack of needles or fasting requirements; some people switching from Zepbound report hunger and regain on the 0.8 mg dose, and some report no loss at 2.5 mg [8]. These are self-selected anecdotes, not evidence of how well the drug works [8].
What is still unknown about Foundayo?
FDA postmarketing requirements include the ACHIEVE-4 report on major adverse cardiovascular events and drug-induced liver injury (trial completion April 2026, report July 2026), an ultrasound trial on retained gastric contents, and a lactation study [9]. Pediatric trials are due at completion in March 2028 (ages 12–17) and March 2031 (ages 6–11), with a pediatric registry running to 2038 [9]. A pregnancy exposure registry and a claims-based pregnancy study are required, along with the MTC registry case series to 2042 [9]. No FDA advisory committee was convened for the approval [9]. ATTAIN-1 reported no hepatic safety signal [4], and ATTAIN-MAINTAIN’s authors flag the absence of a continued-injectable comparator and its one-year horizon as limits on what is known about switching [5].
Sources
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use. Prescribing information. Initial U.S. approval 2026.
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
- Eli Lilly and Company. Foundayo (orforglipron): Now available through LillyDirect.
- Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine. September 16, 2025.
- Nature Medicine. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
- Eli Lilly and Company. Coverage & Savings for Foundayo (orforglipron): Self-Pay & Savings Card.
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge.
- Drugs.com. Foundayo user reviews & ratings.
- US Food and Drug Administration. NDA approval letter for Foundayo (orforglipron) tablets. NDA 220934. 2026.
- PR Newswire. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress.
- The Lancet. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a randomised, phase 3 trial.
- Eli Lilly and Company. How much should I expect to pay for Foundayo (orforglipron)? Foundayo cost information.
- GoodRx. Foundayo 2026 prices, coupons & savings tips.
Frequently asked questions
Are Foundayo and orforglipron the same thing?
Yes. Foundayo is the brand name and orforglipron is the generic name of the same once-daily oral tablet from Eli Lilly, approved by the FDA on April 1, 2026 under NDA 220934. Prescriptions, pharmacy records, and insurance forms may use either name.
Is Foundayo a GLP-1 medication?
Yes. The label identifies Foundayo as a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. It is a small-molecule (non-peptide) tablet taken once daily, while semaglutide and tirzepatide are injectable incretin-based obesity medications.
How quickly do blood levels stabilize after starting?
Steady-state exposure is reached after approximately one week of once-daily dosing, and peak concentration occurs 4 to 8 hours after a dose, per the label. The elimination half-life is approximately 29 to 49 hours.
Can Foundayo be taken with insulin or a sulfonylurea?
The label warns that combining Foundayo with insulin or an insulin secretagogue such as a sulfonylurea can increase the risk of hypoglycemia, including severe episodes, and that reducing the dose of those medicines may be necessary. In Trial 2, 7% of patients on a sulfonylurea with Foundayo reported hypoglycemia versus 0.5% without. Any diabetes-medication change is the prescriber's decision.
Does the weight come back after stopping Foundayo?
The closest published data come from ATTAIN-MAINTAIN's placebo arms: people who stopped injectable therapy without orforglipron kept only 49.2% (tirzepatide cohort) and 37.6% (semaglutide cohort) of their prior weight reduction at week 52. No dedicated Foundayo discontinuation trial appears in the listed sources.
Were older adults included in the trials?
Yes. In the pooled Trials 1 and 2, 13% of Foundayo-treated patients were 65 or older and 1% were 75 or older, and the label reports no overall differences in safety or effectiveness between patients 65 and older and younger adults.
How can you tell the tablet strengths apart?
Each tablet is debossed: 0.8 mg is a pink round tablet marked L and G1; 2.5 mg is light yellow round marked L and G2; 5.5 mg is grayish purple round marked L and G3; and 9 mg is a pink oval tablet marked Lilly and G4.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.